X
Sarepta goes up, PTC goes down – DMD research sways the market
https://pharmaphorum.com/news/dmd-therapy-research-sways-market/
PTC Therapeutics
Pharma collaborates to improve chances of NICE backing Duchenne drugs
Project will initially focus on DMD but could benefit other rare diseases
FDA reviewers slam PTC’s Duchenne drug ahead of meeting
FDA staff not persuaded by patchy clinical trial evidence for Translarna.
Marathon sells Duchenne drug to PTC
PTC says it will make changes to the price after abandoned launch last month.
Sarepta files controversial Duchenne drug in EU
US biotech seeks conditional approval for eteplirsen in EU.
1 2
